Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 March Pharma News FDA approval for ciltacabtagene autoleucel for Relapsed/Refractory Multiple Myeloma Read more
2022 March Science Survival benefits with bortezomib in children with T-cell lymphoblastic leukaemia Read more
2022 March Science UBTF tandem duplication is a recurrent high-risk mutation in pediatric AML Read more
2022 March Prevention A new drug target to overcome obesity-induced chemoresistance in B-acute lymphoblastic leukaem... Read more
2022 March Pharma News FDA: major safety concerns with Ukoniq, PI3K inhibitor drug for treatment of lymphoma Read more
2022 March Clinical trials Consistent benefits of brentuximab vedotin plus chemotherapy for CD30-positive peripheral T-ce... Read more
Top
